Du är här


Galapagos NV: Galapagos presents promising pre-clinical and Phase 1 results with autotaxin inhibitor GLPG1690 at ERS

Mechelen, Belgium; 22 September 2015: Galapagos NV (Euronext&NASDAQ: GLPG)
pre-clinical and Phase 1 results for autotaxin inhibitor GLPG1690 at the
European Respiratory Society Annual Meeting in Amsterdam, Netherlands.
Galapagos expects to file an exploratory Phase 2 study in idiopathic
pulmonary fibrosis before year end. GLPG1690 has potential application in
other pulmonary diseases such as chronic obstructive pulmonary disease
(COPD), as supported by the presentation on pre-clinical findings at ERS this

"Pharmacological profile and efficacy of GLPG1690, a novel ATX inhibitor for
COPD treatment,"
poster PA2129 in Poster Discussion Session: "New targets and modalities for
the treatment of asthma and COPD" (September 28, 2015; Room D201-202, 10:45
AM - 12:45 PM)

Galapagos is the first to show efficacy of an autotaxin inhibitor in
pre-clinical models for COPD and IPF, pointing to novel therapeutic areas for
autotaxin inhibition. The poster shows how GLPG1690 acts as a potent
inhibitor of mouse and human autotaxin (IC50: 100 -500 nM range).
Furthermore, GLPG1690 reduces inflammation in a mouse steroid-resistant
tobacco smoke model to a similar extent as a standard therapy for COPD.

Galapagos also presents the topline results with GLPG1690 in Phase 1 in
healthy human volunteers: "Favorable human safety, pharmacokinetics and
pharmacodynamics of the
autotaxin inhibitor GLPG1690, a potential new treatment in COPD
," oral presentation OA484 in session "Advances in the future treatment of
COPD" (September 27, 2015; Room 2.1, 10:45 AM - 12:45 PM)

GLPG1690 was safe and well tolerated up to a single oral dose of 1500 mg and
up to 1000 mg twice daily for 14 days, with no significant adverse effects on
ECGs, vital signs or laboratory parameters. The compound also showed good
oral bioavailability with a half-life of 5 hours and a dose-proportional
increase in exposure. GLPG1690 showed concentration-dependent reduction of a
relevant biomarker (plasma LPA18:2 levels) with a maximum of approximately
90%. At steady state, continuous reduction of this biomarker levels of>60%
was observed from 0 to 24 hours. The presentation will also include relevant
pre-clinical model data for COPD and IPF with GLPG1690.

Both the presentation and the posters will be made available on the Galapagos
website after the conference.

About Galapagos

Galapagos(Euronext&NASDAQ: GLPG) is a clinical-stage biotechnology company
specialized in the discovery and development of small molecule medicines with
novel modes of action, with a pipeline comprising three Phase 2 programs, two
Phase 1 trials, five pre-clinical studies, and 20 discovery small-molecule
and antibody programs in cystic fibrosis, inflammation, and other
indications. In the field of inflammation, AbbVie and Galapagos signed a
collaboration agreement for the development and commercialization of
filgotinib. Filgotinib is an orally-available, selective inhibitor of JAK1
for the treatment of rheumatoid arthritis and potentially other inflammatory
diseases, currently in Phase 2B studies in RA and in Phase 2 in Crohn's
disease. Galapagos reported good activity and a favorable safety profile in
both the DARWIN 1 and 2 trials in RA. AbbVie and Galapagos also signed a
collaboration agreement in cystic fibrosis to develop and commercialize
molecules that address mutations in the CFTR gene. PotentiatorGLPG1837is
currently in a Phase 1 trial, and corrector GLPG2222 is at the pre-clinical
candidate stage. GLPG1205, a first-in-class inhibitor of GPR84 and
fully-owned by Galapagos, is currently being tested in a Phase 2
proof-of-concept trial in ulcerative colitis patients. GLPG1690, a fully
proprietary, first-in-class inhibitor of autotaxin, has shown favorable
safety in a Phase 1 trial and is expected to enter Phase 2 in idiopathic
pulmonary fibrosis. The Galapagos Group, including fee-for-service
subsidiary Fidelta, has approximately 400 employees, operating from its
Mechelen, Belgium headquarters and facilities in The Netherlands, France, and
Croatia. More info atwww.glpg.com


Galapagos NV
Elizabeth Goodwin, Head of Corporate Communications&IR
Tel: +31 6 2291 6240

Galapagos forward-looking statements

This release may contain forward-looking statements, including without
limitation statements regarding the possibility and timing of the initiation
of Phase 2 activities in idiopathic pulmonary fibrosis, GLPG1690's potential
application in other pulmonary diseases and GLPG1690's safety and/or efficacy
profile. Galapagos cautions the reader that forward-looking statements are
not guarantees of future performance. Forward-looking statements involve
known and unknown risks, uncertainties and other factors which might cause
the actual results, financial condition and liquidity, performance or
achievements of Galapagos, or industry results, to be materially different
from any historic or future results, financial conditions and liquidity,
performance or achievements expressed or implied by such forward-looking
statements. In addition, even if Galapagos' results, performance, financial
condition and liquidity, and the development of the industry in which it
operates are consistent with such forward-looking statements, they may not be
predictive of results or developments in future periods. Among the factors
that may result in differences are the inherent uncertainties associated with
competitive developments, clinical trial and product development activities
and regulatory approval requirements (including that data from Galapagos'
ongoing DARWIN and FITZROY programs with filgotinib may not support
registration or further development of filgotinib due to safety, efficacy or
other reasons), Galapagos' reliance on collaborations with third parties
(including its collaboration partner for filgotinib, AbbVie, who may not
in-license filgotinib or, if it does, may not devote sufficient resources to
the development and commercialization of filgotinib), and estimating the
commercial potential of Galapagos' product candidates. A further list and
description of these risks, uncertainties and other risks can be found in
Galapagos' Securities and Exchange Commission filing and reports, including
in Galapagos' prospectus filed with the SEC on May 14, 2015 and future
filings and reports by Galapagos. Given these uncertainties, the reader is
advised not to place any undue reliance on such forward-looking statements.
These forward-looking statements speak only as of the date of publication of
this document. Galapagos expressly disclaims any obligation to update any
such forward-looking statements in this document to reflect any change in its
expectations with regard thereto or any change in events, conditions or
circumstances on which any such statement is based or that may affect the
likelihood that actual results will differ from those set forth in the
forward-looking statements, unless specifically required by law or


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Galapagos NV via Globenewswire


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.